[Reversing ICU-acquired immunosuppression: an innovative biomarker-guided therapeutic strategy for decreasing sepsis mortality and nosocomial infection rate].

Monneret, G; Lepape, A; Venet, F

[Reversing ICU-acquired immunosuppression: an innovative biomarker-guided therapeutic strategy for decreasing sepsis mortality and nosocomial infection rate]. / Biomarqueurs et thérapeutiques individualisées dans la prise en charge de l'immunosuppression acquise en réanimation.

Monneret, G; Lepape, A; Venet, F.

Affiliation

Monneret G; Laboratoire d'Immunologie Cellulaire, Hospices Civils de Lyon, Hôpital E.-Herriot, 5 Place d'Arsonval, 69437 Lyon cedex 03, France. guillaume.monneret@chu-lyon.fr

Pathol Biol (Paris) ; 59(6): 329-33, 2011 Dec.

Article in Fr | MEDLINE | ID: mdl-21981928

Subject(s)

Cross Infection/epidemiology; Cross Infection/immunology; Immune Tolerance/physiology; Intensive Care Units; Sepsis/mortality; Sepsis/therapy; Biomarkers/analysis; Cross Infection/diagnosis; Cross Infection/therapy; Humans; Intensive Care Units/standards; Models, Biological; Precision Medicine/methods; Prognosis; Sepsis/diagnosis; Sepsis/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cross Infection / Sepsis / Immune Tolerance / Intensive Care Units Type of study: Diagnostic_studies / Prognostic_studies Limits: Humans Language: Fr Journal: Pathol Biol (Paris) Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google